Home » Budget Industry » Navy Working on Better Maintainability, Self-Sufficiency for LCS and Rest of Surface Fleet
Navy Working on Better Maintainability, Self-Sufficiency for LCS and Rest of Surface Fleet
January 20, 2021 5:06 PM
The Japan Maritime Self-Defense Force (JMSDF) training ships JS Kashima (TV 3508), left, and JS Shimayuki (TV 3513), right, sail alongside the Independence-variant littoral combat ship USS Gabrielle Giffords (LCS-10) during an exercise, June 23, 2020. US Navy Photo
Navy officials in Washington and on the waterfront are trying to help the Littoral Combat Ships grow more reliable and maintainable, amid a surface navy-wide effort to focus on crew-level maintenance as a means of improving operational availability.
Surface warfare leaders throughout the Navy last week mused about how to employ new classes of ships such as the Littoral Combat Ship and Expeditionary Sea Base, as the fleet transitions to a new type of operations against peer competitors. While much of the talk around implementing concepts like Distributed Maritime Operations (DMO) and Expeditionary […]
×
Close Signup Modal
Want the latest defense industry news? Sign up for the Breaking Defense newsletter.
We will never sell or share your information without your consent. See our privacy policy.
HJF Announces Changes to its Council of Directors
News provided by
Share this article
Share this article
BETHESDA, Md., Jan. 6, 2021 /PRNewswire/ Ms. Sid Ashworth and Dr. Elder Granger have joined the Council of Directors of the Henry M. Jackson Foundation for the Advancement of Military Medicine. The Honorable Mr. John Dressendorfer has been appointed as the new Chairman of the Council of Directors.
The additions, and appointment of a new Chairman, come as two long-serving members of the Council, The Honorable Mrs. Beverly Byron and former Chairman Philip Odeen, retired from the Council last month.
Ms. Sid Ashworth and Dr. Elder Granger have joined HJF s Council of Directors.
Date Time
Share
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human
Mount Sinai
Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate Emergent’s COVID-19 Human Hyperimmune Globulin (COVID-HIG) product candidate in the first of two Phase 1 studies to support its use for potential post-exposure prophylaxis in individuals at high risk of exposure to SARS-CoV-2, the virus that causes COVID-19, such as front-line health care workers and military personnel.
The first study will evaluate safety and pharmacokinetics of three dose levels administered as a single or repeat IV dose in healthy adults. The second study, once initiated, will evaluate safety, pharmacokinetics, and pharmacodynamics of two dose levels administered as a single IV dose to adults with SARS-CoV-2 infection, whether asymptomatic or with mild COVID-19.